Subject(s)
Amisulpride , Antipsychotic Agents , Olanzapine , Schizophrenia , Humans , Olanzapine/administration & dosage , Olanzapine/therapeutic use , Amisulpride/administration & dosage , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , Schizophrenia/drug therapy , Drug Therapy, Combination , Male , Female , Age of OnsetABSTRACT
Objective: Methylphenidate, a psychostimulant agent, is used in first-line psychopharmacological treatment in children and adolescents with attention-deficit/hyperactivity disorder. Common side effects associated with methylphenidate use in children and adolescents are insomnia, anorexia, headache, and nausea. Thrombocytopenia, nasal bleeding and menstrual bleeding disorders are very rarely reported during methylphenidate use. One of the least expected side effects during methylphenidate usage is menorrhagia. Method : In this article, we report methylphenidate monotherapy-induced menorrhagia in two adolescent identical twins. To our knowledge, this is the first report of menorrhagia associated with methylphenidate use in children and adolescents. Results: In both cases, menorrhagia has started after methylphenidate monotherapy and stopped after discontinuation. Other possible etiologies have excluded with clinical and laboratory evaluations. Naranjo Adverse Drug Reaction Probability Score was found 7, indicates probable side effect. Conclusion: Menorrhagia is a rare adverse effect of methylphenidate use and clinicians should be aware of this phenomenon.
ABSTRACT
ABSTRACT: Aripiprazole is an atypical antipsychotic commonly used in the treatment of psychiatric disorders, such as schizophrenia, bipolar disorder, and irritability associated with autism spectrum disorder. Common adverse effects associated with aripiprazole usage in children and adolescents are nausea, vomiting, extrapyramidal adverse effects, akathisia, sedation, tremor, and increased appetite. Enuresis is one of the least expected adverse effects during aripiprazole use. The pathophysiology of aripiprazole-induced enuresis has not been fully clarified. To our knowledge, our report presents enuresis related to aripiprazole use at the lowest dose in the literature. In this report, we present the case of a 9-year-old boy who developed nocturnal enuresis after the beginning of low-dose aripiprazole treatment.
Subject(s)
Antipsychotic Agents , Autism Spectrum Disorder , Nocturnal Enuresis , Schizophrenia , Adolescent , Antipsychotic Agents/adverse effects , Aripiprazole/adverse effects , Autism Spectrum Disorder/drug therapy , Child , Humans , Male , Nocturnal Enuresis/chemically induced , Nocturnal Enuresis/drug therapy , Schizophrenia/drug therapyABSTRACT
ABSTRACT: Fluoxetine, a selective serotonin reuptake inhibitor, is an efficacious medication in social anxiety disorder with a generally well-tolerated adverse effect profile. However, infrequent side effects may occur during treatment. Here, we report a case of systemic hypertension in a 12-year-old female patient with social anxiety disorder receiving fluoxetine treatment. To the best of our knowledge, this is the first report of fluoxetine-induced systemic hypertension in children and adolescences.
